A-674563 is an Orally Active and Selective Akt1 Inhibitor
Posted On 2021-05-05
Akt1 belongs to the Akt subfamily of serine/threonine kinases, which contains the SH2 (SRC homologous 2-like) domain. Specifically, Akt kinase is the central node of the signal transduction pathway, which is important for cell transformation and tumor progression. Besides, Akt is a key mediator of growth factor-induced neuronal survival in the developing nervous system. Moreover, Akt1 is crucial for the transmission of growth-promoting signals. The change of Akt activity is the most common change in malignant tumor cells. Furthermore, Akt (Akt1) initially transformed the oncogene of retrovirus Akt8. This promotes the proliferation, survival, apoptosis resistance, transformation, and metastasis of leukemia cells. Therefore, Akt represents an important molecular target for AML treatment.
Interestingly, Akt1 is activated by phosphorylation at two key regulatory sites thr308 and ser473. Active Akt1 phosphorylates many downstream cell targets in the cytoplasm and nucleus. Akt1 is for phosphorylating proteins that regulate cell survival and apoptosis. Importantly, Akt1 is hyperphosphorylated and hyperactive in >50% of human tumors. The increase of Akt1 phosphorylation was related to the poor clinical prognosis. Here, we will introduce a potent and selective Akt1 inhibitor, A-674563.
A-674563 is an Orally Active and Selective Akt1 Inhibitor.
First of all, A-674563 is an orally active and selective Akt1 inhibitor with a Ki of 11 nM. Meanwhile, A-674563 slows the proliferation of tumor cells with an EC50 of 0.4 μM.
In the second place, A563 with 0-10 µM significantly decreases GSK3 and MDM2 phosphorylation in STS cells. Nonetheless, A563 inhibits all STS cell lines activity, with IC50 values at 48 hours ranging from 0.22 µM (SW684) to 0.35 µM (SKLMS1). Obviously, A563 induces G2 cell cycle arrest and apoptosis in STS cells. Particularly, A563 upregulates the expression of GADD45A independent of p53.
Last but not the least, A-674563 with 40 mg/kg/d by p.o. shows no significant monotherapy activity. the combination therapy (A-674563+paclitaxel) has significantly improved efficacy in the PC-3 prostate cancer xenograft model. A-674563 increases plasma insulin in an oral glucose tolerance test. Additionally, A563 with 20 mg/kg/bid by p.o. exhibits slow tumor growth and a significant difference in tumor volume without significant weight loss of mice.
All in all, A-674563 is an orally active and selective Akt1 inhibitor.